Your browser is no longer supported. Please, upgrade your browser.
Settings
CARA Cara Therapeutics, Inc. daily Stock Chart
CARA [NASD]
Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.18 Insider Own2.80% Shs Outstand40.79M Perf Week-0.56%
Market Cap790.10M Forward P/E- EPS next Y-2.32 Insider Trans-16.75% Shs Float34.73M Perf Month14.62%
Income-41.60M PEG- EPS next Q-0.57 Inst Own62.50% Short Float15.77% Perf Quarter38.56%
Sales7.90M P/S100.01 EPS this Y-15.50% Inst Trans2.04% Short Ratio8.12 Perf Half Y-8.63%
Book/sh3.38 P/B5.73 EPS next Y2.50% ROA- Target Price25.80 Perf Year60.88%
Cash/sh3.96 P/C4.90 EPS next 5Y- ROE- 52W Range11.46 - 24.30 Perf YTD49.00%
Dividend- P/FCF- EPS past 5Y- ROI-56.90% 52W High-20.29% Beta2.71
Dividend %- Quick Ratio4.20 Sales past 5Y2.40% Gross Margin- 52W Low69.02% ATR0.83
Employees37 Current Ratio4.20 Sales Q/Q- Oper. Margin- RSI (14)66.08 Volatility4.21% 4.41%
OptionableYes Debt/Eq0.01 EPS Q/Q- Profit Margin- Rel Volume0.81 Prev Close19.52
ShortableYes LT Debt/Eq0.01 EarningsMar 12 AMC Payout- Avg Volume673.96K Price19.37
Recom1.70 SMA2011.13% SMA5018.39% SMA2007.45% Volume547,844 Change-0.77%
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Aug-08-16Reiterated Needham Buy $27 → $23
Feb-29-16Reiterated Laidlaw Buy $30 → $17
Nov-04-15Initiated Cantor Fitzgerald Buy
Jul-24-15Reiterated Needham Buy $22 → $27
Mar-18-19 07:48PM  Edited Transcript of CARA earnings conference call or presentation 12-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 01:01PM  Here's Why Cara Therapeutics Stock Rose as Much as 13.9% Today Motley Fool +11.76%
12:15PM  These Four Marijuana Stocks Are Raising Eyebrows on Wednesday ACCESSWIRE
12:19AM  Cara Therapeutics Inc (CARA) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-12-19 05:35PM  Stocks making the biggest moves after hours: Switch, Clearwater Paper and more CNBC
05:20PM  Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:27PM  Cara: 4Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
10:00AM  Top Cannabis Plays-THC Therapeutics, Inc ACCESSWIRE
Mar-07-19 08:57AM  Athersys (ATHX) Q4 Earnings: What's in Store for the Stock? Zacks
08:51AM  Is a Beat in Store for Catabasis (CATB) This Earnings Season? Zacks
Mar-05-19 04:01PM  Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019 GlobeNewswire
10:10AM  Top Marijuana Stocks on the NASDAQ Investopedia
Mar-04-19 06:41AM  Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings? Zacks
Mar-03-19 10:15AM  Better Buy: Cara Therapeutics vs. Scotts Miracle-Gro Company Motley Fool
Feb-28-19 10:21AM  New Cannabis Products Which Could Disrupt the Industry in 2019 Investopedia
Feb-22-19 04:43PM  What's in Store for Vericel (VCEL) This Earnings Season? Zacks
Feb-15-19 08:20AM  Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-13-19 01:47PM  Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? InvestorPlace
Feb-12-19 09:00AM  Biotech Plays in the News You Should Know ACCESSWIRE
Feb-11-19 01:56PM  Here's Why Cara Therapeutics Stock Rose 17.3% in January Motley Fool
Feb-08-19 12:10PM  These 4 Marijuana Stocks Are Looking Strong ACCESSWIRE +10.31%
Feb-06-19 02:45PM  Watch These Marijuana Stocks Hit The Ground Running On Wednesday (2/6/19) ACCESSWIRE
Feb-05-19 08:00AM  Biotech Stocks to Watch ACCESSWIRE
Jan-31-19 04:09PM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
08:30AM  Biotechs Investors Are Flocking To ACCESSWIRE
Jan-29-19 08:30AM  Cannabis and Biotech Stocks that Could Explode ACCESSWIRE
Jan-28-19 08:00AM  Biotech Stocks to Watch this Week ACCESSWIRE
Jan-24-19 12:08PM  Is Cara Therapeutics a Buy? Motley Fool
08:10AM  Consolidated Research: 2019 Summary Expectations for First Data, IDEXX Laboratories, CMS Energy, Worthington Industries, Triumph Group, and Cara Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-18-19 09:36AM  With Trial Results Due, This Could Be a Breakout Year for Cara Stock InvestorPlace
Jan-15-19 11:10AM  Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results Benzinga
Jan-10-19 09:19PM  Here's Why Cara Therapeutics Fell 28.5% in December Motley Fool
Jan-07-19 07:00AM  Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA (CR845/ difelikefalin) Injection in Hemodialysis Patients with Pruritus GlobeNewswire +5.34%
Jan-04-19 05:11PM  Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine? Investor's Business Daily +5.34%
Jan-03-19 05:43PM  Cara (CARA) Up on IDMC's Recommendation to Continue Trial Zacks
Jan-02-19 07:00AM  Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA Injection in Hemodialysis Patients with Pruritus GlobeNewswire +12.00%
Dec-23-18 03:38AM  Is Casa Therapeutics Inc (CARA) Going to Burn These Hedge Funds? Insider Monkey
Dec-19-18 12:20PM  Cara Therapeutics Stock Could Outperform in 2019 InvestorPlace
Dec-18-18 08:45AM  4 Marijuana Stocks To Watch On Tuesday 12/18/2018 ACCESSWIRE
07:33AM  Jim Cramer Advises His Viewers On Apache, Waste Management And More Benzinga
Dec-17-18 06:48PM  Cramer's lightning round: 'Yield will protect you in this awful market' CNBC
09:20AM  A Solution to the Nation's Current Opioid Overdose Epidemic and The World's Leading Cause of Disability ACCESSWIRE
Dec-14-18 06:30AM  This Unknown Stock With A Market Opportunity Rivaling Cannabis Could Offer Big Upside For Investors ACCESSWIRE
Dec-11-18 10:20AM  CBD Industry Growth Sparks Momentum For Marijuana Stocks ACCESSWIRE
Dec-10-18 10:35AM  Alternatives to Watch ACCESSWIRE
Dec-03-18 10:46AM  The Trade War Could Be a Positive Catalyst for Cara Therapeutics Stock InvestorPlace
Dec-02-18 09:17AM  Why Cara Therapeutics Is Up 50% in 2018 Motley Fool
Nov-21-18 11:30AM  Opioid Alternatives Could Make Investors Major Gains ACCESSWIRE
Nov-16-18 09:00AM  12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure Benzinga
Nov-12-18 08:20AM  Research Report Identifies DXP Enterprises, Diebold Nixdorf, Fitbit, Nevro, Plains All American Pipeline, and Cara Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-10-18 09:27AM  Edited Transcript of CARA earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-08-18 04:01PM  Cara Therapeutics to Present at November Investor Conferences GlobeNewswire
Nov-06-18 06:00PM  Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:57PM  Cara: 3Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 08:53AM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Nov-01-18 12:20PM  Cannabis and Biotech Stocks That Could Bounce ACCESSWIRE +5.71%
Oct-30-18 04:01PM  Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018 GlobeNewswire
Oct-28-18 06:33AM  Better Buy: Cara Therapeutics, Inc. vs. Scotts Miracle-Gro Company Motley Fool
Oct-23-18 10:09AM  Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In? Investopedia
07:00AM  Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer GlobeNewswire
Oct-19-18 02:00PM  9 Marijuana Stocks to Play the Pot Craze InvestorPlace
Oct-18-18 08:55AM  Investor Expectations to Drive Momentum within Teradata, Liberty TripAdvisor, CPI Card Group, Cara Therapeutics, Ocular Therapeutix, and G-III Apparel Group, LTD Discovering Underlying Factors of Influence GlobeNewswire
Oct-10-18 01:31PM  Here's Why Cara Therapeutics Rose 18.7% in September Motley Fool -5.30%
Oct-07-18 06:31AM  Better Buy: GW Pharmaceuticals vs. Cara Therapeutics Motley Fool
Sep-26-18 04:01PM  Cara Therapeutics to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-21-18 03:32PM  Cantor Fitzgerald's 7 Buys For 7 Biotechs Benzinga
Sep-19-18 10:30AM  CBD Stocks Set to Explode ACCESSWIRE
08:00AM  Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Cara Therapeutics ACCESSWIRE
Sep-14-18 01:05PM  Major Stem Cell Breakthroughs Giving Investors Big Opportunity ACCESSWIRE
Sep-13-18 11:55AM  Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate Benzinga
08:45AM  Better Buy: Cara Therapeutics Inc. vs. Fresenius Medical Care AG & Co. Motley Fool
Sep-05-18 04:01PM  Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress GlobeNewswire
01:26AM  Here's Why Cara Therapeutics Rose 12.5% in August Motley Fool
Aug-27-18 07:40AM  Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-22-18 03:40AM  Edited Transcript of CARA earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-19-18 06:33AM  3 Reasons Cara Therapeutics Is a Great Pick for Aggressive Investors Motley Fool
Aug-13-18 01:45PM  4 Cannabis Stocks In Uptrends This Week Benzinga
Aug-08-18 05:35PM  Biotech and Cannabis Companies Set to Own The Future ACCESSWIRE +5.23%
Aug-07-18 06:30PM  Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:26PM  Cara: 2Q Earnings Snapshot Associated Press
04:01PM  Cara Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
07:00AM  Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus GlobeNewswire
Aug-06-18 07:00AM  Cara Therapeutics Appoints Christopher A. Posner to Board of Directors GlobeNewswire
Jul-31-18 04:05PM  Cara Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
Jul-27-18 07:35AM  Initiating Free Research Reports on Celgene and Three Other Biotech Equities ACCESSWIRE
Jul-25-18 07:30AM  This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up ACCESSWIRE
Jul-23-18 04:02PM  Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-19-18 08:00AM  Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA PR Newswire
Jul-18-18 08:53PM  Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock GlobeNewswire -8.24%
04:50PM  What Happened in the Stock Market Today Motley Fool
08:20AM  Today's Research Reports on Trending Tickers: Cara Therapeutics and Cellectar Biosciences ACCESSWIRE
Jul-17-18 04:23PM  Cara Therapeutics Announces Proposed Offering of Common Stock GlobeNewswire
02:22PM  The Picture for Cara Therapeutics Just Got Clearer Motley Fool
Jul-15-18 05:02PM  Here's Why Cara Therapeutics Jumped 56.5% in the First Half of 2018 Motley Fool
Jul-11-18 07:00AM  Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients GlobeNewswire
Jul-06-18 07:12PM  Cramer's lightning round: Buy Merck on its superior anti-... CNBC Videos
06:48PM  Cramer's lightning round: Buy Merck on its superior anti-cancer portfolio CNBC
Jul-05-18 06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mohindru ManiCFO & Chief Strategy OfficerMar 13Option Exercise14.0616,041225,53624,067Mar 15 04:42 PM
Mohindru ManiCFO & Chief Strategy OfficerMar 13Sale19.1216,041306,7048,026Mar 15 04:42 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 13Sale18.8716,803317,073122,779Mar 14 05:13 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 12Sale17.503,19755,948139,582Mar 14 05:13 PM
CHALMERS DEREK TPresident & CEOMar 01Sale17.049,792166,856943,996Mar 05 04:53 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentFeb 28Sale17.501,50026,250142,779Mar 04 05:49 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentFeb 25Sale17.502,20038,500144,279Feb 27 05:29 PM
CHALMERS DEREK TPresident & CEOFeb 01Sale14.9920,000299,800953,788Feb 05 04:27 PM
CHALMERS DEREK TPresident & CEOJan 04Sale15.045,00075,200973,788Jan 04 04:22 PM
CHALMERS DEREK TPresident & CEOJan 02Sale13.1315,000196,950978,788Jan 04 04:22 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentDec 28Sale12.534,30053,879146,479Jan 02 05:56 PM
CHALMERS DEREK TPresident & CEODec 28Sale12.5315,825198,287993,788Jan 02 05:55 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Dec 28Sale12.513,10038,7816,386Jan 02 05:56 PM
Mohindru ManiCFO & Chief Strategy OfficerDec 28Sale12.554,50056,4758,026Jan 02 05:54 PM
CHALMERS DEREK TPresident & CEODec 03Sale18.1720,000363,400971,392Dec 06 04:16 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentDec 03Sale18.363,00055,080139,000Dec 06 04:18 PM
Mohindru ManiCFO & Chief Strategy OfficerNov 15Option Exercise14.0616,042225,55116,042Nov 16 04:22 PM
Mohindru ManiCFO & Chief Strategy OfficerNov 15Sale18.5016,042296,7770Nov 16 04:22 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentNov 01Option Exercise2.0540,00082,000145,000Nov 05 08:25 PM
CHALMERS DEREK TPresident & CEONov 01Sale18.7820,000375,600991,392Nov 02 05:35 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentNov 01Sale18.773,00056,310142,000Nov 05 08:25 PM
Mohindru ManiCFO & Chief Strategy OfficerOct 17Option Exercise14.0616,042225,55116,042Oct 19 04:32 PM
Stauffer Joseph WilliamChief Medical OfficerOct 17Sale20.1311,442230,3472,000Oct 19 04:34 PM
Mohindru ManiCFO & Chief Strategy OfficerOct 17Sale20.1916,042323,8880Oct 19 04:32 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentOct 01Sale23.993,00071,97095,000Oct 03 04:09 PM
CHALMERS DEREK TPresident & CEOOct 01Sale23.7920,000475,8001,011,392Oct 03 04:08 PM
CHALMERS DEREK TPresident & CEOSep 04Sale19.7120,000394,2001,031,392Sep 06 05:34 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentSep 04Sale19.813,00059,43098,000Sep 06 05:33 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentAug 20Sale18.893,00056,670101,000Aug 22 05:26 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentAug 06Option Exercise2.2510,00022,500114,000Nov 05 08:21 PM
CHALMERS DEREK TPresident & CEOJul 10Sale20.6420,000412,8001,051,392Jul 12 04:42 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentJul 02Sale19.003,00057,000104,000Jul 05 05:00 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentJun 01Sale15.493,00046,470107,000Jun 05 07:15 PM
Menzaghi Frederique Ph.D.Sr VP-Research & DevelopmentMay 23Sale15.199,000136,710110,000May 25 04:22 PM